patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_721758 | REC_0003301 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 4.6 | 72 | male | 1 | 12 | 5.1 | 6 | osimertinib 80 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:57.660167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671200 | REC_0003302 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 14.5 | 71 | female | 1 | 11 | 6.1 | 1 | osimertinib 80 mg daily | 5.9 | false | MSS | 2026-03-15T05:35:57.660425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409527 | REC_0003303 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 12.9 | 68 | female | 1 | 22 | 5.4 | 1 | osimertinib 80 mg daily | 29.9 | true | MSI-H | 2026-03-15T05:35:57.660796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371368 | REC_0003304 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 3 | 73 | female | 1 | 38 | 5.8 | 7 | pembrolizumab 200 mg q3w | 10.1 | false | MSS | 2026-03-15T05:35:57.661036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514933 | REC_0003305 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.5 | 70 | female | 2 | 47 | 4.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:35:57.661271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946563 | REC_0003306 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 11.4 | 76 | male | 3 | 14 | 7.2 | 2 | alectinib 600 mg BID | 23.8 | false | MSS | 2026-03-15T05:35:57.661514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965392 | REC_0003307 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 10.2 | 63 | male | 0 | 8 | 5.3 | 5 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:57.661751+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534397 | REC_0003308 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 8.6 | 79 | male | 0 | 58 | 5.9 | 4 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:35:57.661984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826517 | REC_0003309 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 13.8 | 65 | female | 1 | 12 | 3.9 | 7 | sotorasib 960 mg daily | 7.9 | true | MSS | 2026-03-15T05:35:57.662223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846790 | REC_0003310 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13 | 69 | female | 0 | 23 | 6.5 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.662458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270220 | REC_0003311 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.9 | 76 | female | 2 | 8 | 4.4 | 8 | osimertinib 80 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:57.662689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826642 | REC_0003312 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 13 | 11.5 | 62 | female | 0 | 19 | 5.5 | 7 | entrectinib 600 mg daily | 11 | true | MSI-H | 2026-03-15T05:35:57.662923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963721 | REC_0003313 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 15.5 | 64 | male | 1 | 15 | 4.8 | 6 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:35:57.663157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336793 | REC_0003314 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 15.9 | 70 | female | 3 | 21 | 4 | 6 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.663388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850872 | REC_0003315 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 10 | 70 | female | 1 | 8 | 6.1 | 1 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:57.663616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895826 | REC_0003316 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 3.7 | 86 | female | 1 | 34 | 6.1 | 7 | pembrolizumab 200 mg q3w | 10.8 | false | MSS | 2026-03-15T05:35:57.663886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721501 | REC_0003317 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 8.7 | 59 | male | 0 | 19 | 7.7 | 8 | alectinib 600 mg BID | 13.4 | false | MSS | 2026-03-15T05:35:57.664178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931140 | REC_0003318 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.9 | 70 | female | 1 | 12 | 5.1 | 7 | pembrolizumab 200 mg q3w | 7.1 | true | MSS | 2026-03-15T05:35:57.664429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284104 | REC_0003319 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5 | 73 | female | 2 | 92 | 6.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.3 | true | MSS | 2026-03-15T05:35:57.664677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171471 | REC_0003320 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 11.4 | 89 | male | 1 | 14 | 5 | 1 | sotorasib 960 mg daily | 14.6 | true | MSI-H | 2026-03-15T05:35:57.664923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251348 | REC_0003321 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.3 | 68 | female | 1 | 12 | 5.2 | 3 | osimertinib 80 mg daily | 12.7 | true | MSI-H | 2026-03-15T05:35:57.665158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949721 | REC_0003322 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 8.1 | 70 | female | 2 | 6 | 4.8 | 7 | alectinib 600 mg BID | 9.5 | true | MSS | 2026-03-15T05:35:57.665390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946092 | REC_0003323 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 11.2 | 66 | male | 0 | 12 | 4.3 | 2 | sotorasib 960 mg daily | 28.7 | false | MSI-H | 2026-03-15T05:35:57.665627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583054 | REC_0003324 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 3.9 | 50 | female | 0 | 26 | 4.3 | 4 | entrectinib 600 mg daily | 5.8 | false | MSS | 2026-03-15T05:35:57.665859+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422275 | REC_0003325 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 20.1 | 64 | male | 0 | 7 | 5.2 | 6 | osimertinib 80 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:35:57.666094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142480 | REC_0003326 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 13 | 64 | male | 0 | 17 | 5.8 | 4 | sotorasib 960 mg daily | 11 | false | MSS | 2026-03-15T05:35:57.666327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852597 | REC_0003327 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 13 | 65 | male | 0 | 13 | 6.7 | 6 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:57.666560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985132 | REC_0003328 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 19.2 | 65 | female | 1 | 21 | 6.1 | 2 | osimertinib 80 mg daily | 20.5 | false | MSS | 2026-03-15T05:35:57.666795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326225 | REC_0003329 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 12.3 | 69 | female | 1 | 15 | 6.3 | 7 | osimertinib 80 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:57.667097+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592991 | REC_0003330 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 13.1 | 74 | female | 1 | 25 | 6.6 | 1 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:57.667337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556558 | REC_0003331 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8.3 | 52 | male | 0 | 72 | 6.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.8 | false | MSS | 2026-03-15T05:35:57.667570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380788 | REC_0003332 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 5.9 | 69 | female | 0 | 12 | 7 | 1 | pembrolizumab 200 mg q3w | 12.6 | true | MSS | 2026-03-15T05:35:57.667801+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981113 | REC_0003333 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12 | 81 | male | 1 | 19 | 3.9 | 3 | alectinib 600 mg BID | 8.3 | true | MSS | 2026-03-15T05:35:57.668035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768470 | REC_0003334 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.6 | 52 | female | 0 | 23 | 5.6 | 6 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:57.668314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909717 | REC_0003335 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 13.6 | 71 | female | 2 | 19 | 6.9 | 7 | entrectinib 600 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:57.668563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484315 | REC_0003336 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 18.9 | 70 | male | 1 | 19 | 5 | 7 | osimertinib 80 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:57.668813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707292 | REC_0003337 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 12.6 | 60 | female | 1 | 15 | 6.8 | 6 | osimertinib 80 mg daily | 5.8 | false | MSS | 2026-03-15T05:35:57.669055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147262 | REC_0003338 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 6.9 | 85 | female | 1 | 19 | 5.2 | 5 | pembrolizumab 200 mg q3w | 8.3 | false | MSS | 2026-03-15T05:35:57.669288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382483 | REC_0003339 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 15.1 | 84 | female | 1 | 9 | 6.3 | 1 | sotorasib 960 mg daily | 7.6 | true | MSS | 2026-03-15T05:35:57.669525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334615 | REC_0003340 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 15 | 5.3 | 73 | female | 2 | 31 | 4.2 | 3 | pembrolizumab 200 mg q3w | 26.5 | true | MSS | 2026-03-15T05:35:57.669758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799815 | REC_0003341 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 11.9 | 50 | female | 0 | 15 | 5.6 | 4 | entrectinib 600 mg daily | 14 | false | MSS | 2026-03-15T05:35:57.669998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149033 | REC_0003342 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 7.9 | 76 | female | 2 | 12 | 2.2 | 7 | osimertinib 80 mg daily | 5.9 | false | MSS | 2026-03-15T05:35:57.670303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_470119 | REC_0003343 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.7 | 81 | female | 2 | 23 | 5.2 | 3 | osimertinib 80 mg daily | 20 | true | MSS | 2026-03-15T05:35:57.670545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964871 | REC_0003344 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.4 | 68 | male | 1 | 76 | 5.2 | 9 | carboplatin + paclitaxel + pembrolizumab | 13.2 | true | MSS | 2026-03-15T05:35:57.670775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814235 | REC_0003345 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 3.9 | 57 | male | 0 | 19 | 7.6 | 2 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:35:57.671016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633985 | REC_0003346 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.6 | 80 | female | 2 | 14 | 6.6 | 6 | osimertinib 80 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:57.671250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995451 | REC_0003347 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5.4 | 65 | female | 1 | 58 | 3.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:35:57.671483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133881 | REC_0003348 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.6 | 60 | male | 1 | 12 | 3.1 | 3 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:57.671712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824564 | REC_0003349 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 8.2 | 68 | female | 1 | 10 | 4.1 | 6 | pembrolizumab 200 mg q3w | 7.2 | false | MSS | 2026-03-15T05:35:57.671941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454644 | REC_0003350 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 8.3 | 70 | male | 2 | 14 | 6.5 | 4 | osimertinib 80 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:57.672213+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813741 | REC_0003351 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 15.4 | 71 | male | 1 | 10 | 4.5 | 7 | osimertinib 80 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:57.672458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542217 | REC_0003352 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.5 | 59 | male | 1 | 61 | 5.2 | 7 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:35:57.672692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278371 | REC_0003353 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 31 | 12.9 | 74 | female | 2 | 10 | 6.9 | 0 | osimertinib 80 mg daily | 51.7 | false | MSI-H | 2026-03-15T05:35:57.672931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425957 | REC_0003354 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 9 | 6.2 | 67 | female | 1 | 22 | 7.5 | 1 | pembrolizumab 200 mg q3w | 25.1 | true | MSS | 2026-03-15T05:35:57.673164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214210 | REC_0003355 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 10.6 | 61 | male | 1 | 19 | 5.7 | 6 | osimertinib 80 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:57.673467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929124 | REC_0003356 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 9.2 | 61 | female | 0 | 65 | 7.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.3 | false | MSS | 2026-03-15T05:35:57.673710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546591 | REC_0003357 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 17.6 | 77 | female | 2 | 7 | 2.5 | 6 | entrectinib 600 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:57.673942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391283 | REC_0003358 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 34 | 6.6 | 69 | female | 0 | 49 | 6.4 | 7 | pembrolizumab 200 mg q3w | 18.5 | false | MSS | 2026-03-15T05:35:57.674170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505184 | REC_0003359 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 24 | 15.4 | 52 | female | 0 | 14 | 6.4 | 0 | entrectinib 600 mg daily | 46.8 | true | MSI-H | 2026-03-15T05:35:57.674406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836103 | REC_0003360 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 4.3 | 66 | female | 0 | 11 | 4.4 | 4 | sotorasib 960 mg daily | 18.1 | false | MSS | 2026-03-15T05:35:57.674640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723517 | REC_0003361 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 10.4 | 84 | female | 2 | 10 | 5.8 | 1 | osimertinib 80 mg daily | 30.2 | false | MSI-H | 2026-03-15T05:35:57.674875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700674 | REC_0003362 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.2 | 66 | female | 1 | 10 | 6.9 | 3 | osimertinib 80 mg daily | 8 | true | MSS | 2026-03-15T05:35:57.675106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830149 | REC_0003363 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 38 | 14.8 | 54 | female | 0 | 11 | 4.9 | 7 | alectinib 600 mg BID | 14.8 | true | MSS | 2026-03-15T05:35:57.675340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644066 | REC_0003364 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 11.6 | 67 | male | 1 | 18 | 4 | 1 | osimertinib 80 mg daily | 18.1 | true | MSI-H | 2026-03-15T05:35:57.675574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738880 | REC_0003365 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 19.2 | 66 | male | 1 | 18 | 7.8 | 0 | entrectinib 600 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:57.675812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752369 | REC_0003366 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 10.8 | 61 | female | 0 | 19 | 5.5 | 5 | entrectinib 600 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:57.676048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248686 | REC_0003367 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 6.2 | 61 | female | 1 | 17 | 6.3 | 1 | osimertinib 80 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:57.676394+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263567 | REC_0003368 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.2 | 65 | female | 0 | 38 | 4 | 7 | pembrolizumab 200 mg q3w | 11.1 | false | MSS | 2026-03-15T05:35:57.676743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634343 | REC_0003369 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 7.1 | 60 | female | 0 | 13 | 5.1 | 2 | pembrolizumab 200 mg q3w | 19.2 | false | MSS | 2026-03-15T05:35:57.677023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683779 | REC_0003370 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 16 | 70 | male | 1 | 11 | 7.8 | 6 | sotorasib 960 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:35:57.677287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325370 | REC_0003371 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 6.3 | 82 | female | 1 | 17 | 5.6 | 4 | pembrolizumab 200 mg q3w | 19.4 | true | MSS | 2026-03-15T05:35:57.677526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847728 | REC_0003372 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 9.8 | 57 | female | 1 | 10 | 5.6 | 6 | osimertinib 80 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:57.677765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291298 | REC_0003373 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.2 | 69 | male | 0 | 22 | 5.2 | 4 | alectinib 600 mg BID | 15.6 | false | MSI-H | 2026-03-15T05:35:57.678007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607056 | REC_0003374 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 25 | 10.4 | 56 | male | 1 | 0 | 3 | 0 | entrectinib 600 mg daily | 37.6 | false | MSI-H | 2026-03-15T05:35:57.678246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322731 | REC_0003375 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 16.3 | 53 | male | 0 | 19 | 7.7 | 6 | entrectinib 600 mg daily | 13.9 | true | MSS | 2026-03-15T05:35:57.678480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926317 | REC_0003376 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8.9 | 90 | female | 0 | 6 | 6.9 | 9 | alectinib 600 mg BID | 12.4 | false | MSS | 2026-03-15T05:35:57.678711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555695 | REC_0003377 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 23 | 6.1 | 74 | male | 2 | 2 | 6.2 | 0 | pembrolizumab 200 mg q3w | 28 | true | MSS | 2026-03-15T05:35:57.678944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575732 | REC_0003378 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.1 | 73 | female | 2 | 39 | 7.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.9 | false | MSS | 2026-03-15T05:35:57.679178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321597 | REC_0003379 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 17.6 | 84 | female | 1 | 8 | 4.9 | 0 | entrectinib 600 mg daily | 50.1 | true | MSI-H | 2026-03-15T05:35:57.679420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974636 | REC_0003380 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 13.9 | 57 | female | 1 | 9 | 7.2 | 2 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:57.679666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899038 | REC_0003381 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 17 | 64 | male | 1 | 22 | 5.1 | 3 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:57.680013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804278 | REC_0003382 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 5.6 | 64 | female | 1 | 25 | 7 | 2 | entrectinib 600 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:57.680348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728861 | REC_0003383 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 6.1 | 62 | female | 0 | 21 | 7.7 | 4 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:35:57.680609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370667 | REC_0003384 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.9 | 82 | female | 1 | 24 | 8.2 | 3 | alectinib 600 mg BID | 16.3 | true | MSS | 2026-03-15T05:35:57.680854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751032 | REC_0003385 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 5.5 | 67 | female | 0 | 20 | 6.5 | 5 | alectinib 600 mg BID | 7.9 | true | MSS | 2026-03-15T05:35:57.681090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445610 | REC_0003386 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 4.4 | 80 | female | 2 | 12 | 5.2 | 6 | entrectinib 600 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:57.681329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344652 | REC_0003387 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 12.8 | 61 | male | 1 | 12 | 6.6 | 6 | sotorasib 960 mg daily | 12.4 | false | MSI-H | 2026-03-15T05:35:57.681587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338370 | REC_0003388 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 7.9 | 65 | male | 0 | 16 | 4.7 | 5 | osimertinib 80 mg daily | 13.9 | true | MSS | 2026-03-15T05:35:57.681839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694243 | REC_0003389 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 7.3 | 79 | female | 2 | 9 | 6.4 | 1 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:57.682098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396740 | REC_0003390 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10 | 72 | male | 2 | 9 | 4.2 | 7 | alectinib 600 mg BID | 6.3 | false | MSI-H | 2026-03-15T05:35:57.682350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532652 | REC_0003391 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 13.5 | 88 | male | 2 | 4 | 4.7 | 1 | osimertinib 80 mg daily | 29.3 | false | MSI-H | 2026-03-15T05:35:57.682591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330936 | REC_0003392 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 6.9 | 70 | female | 0 | 11 | 4.7 | 6 | entrectinib 600 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:57.682825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626722 | REC_0003393 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.6 | 60 | male | 0 | 15 | 7.2 | 2 | sotorasib 960 mg daily | 14.2 | true | MSS | 2026-03-15T05:35:57.683063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551037 | REC_0003394 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 18 | 6.4 | 69 | female | 0 | 18 | 5.5 | 0 | osimertinib 80 mg daily | 33.9 | true | MSS | 2026-03-15T05:35:57.683429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474257 | REC_0003395 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 7.7 | 55 | female | 1 | 25 | 7.5 | 4 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:57.683670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873973 | REC_0003396 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 13.6 | 86 | female | 2 | 8 | 5 | 5 | sotorasib 960 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:57.683907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466643 | REC_0003397 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11.2 | 62 | male | 1 | 9 | 8 | 1 | alectinib 600 mg BID | 14 | false | MSI-H | 2026-03-15T05:35:57.684207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453025 | REC_0003398 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 1.5 | 68 | female | 0 | 7 | 3.1 | 7 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:57.684446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856473 | REC_0003399 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 14.2 | 64 | male | 1 | 3 | 6.2 | 2 | alectinib 600 mg BID | 19.4 | false | MSI-H | 2026-03-15T05:35:57.684686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105889 | REC_0003400 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 8.8 | 72 | female | 1 | 6 | 5.9 | 3 | sotorasib 960 mg daily | 17.9 | false | MSS | 2026-03-15T05:35:57.684915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.